Y Combinator is a startup accelerator that invests in a large number of startups twice a year. It created a new model for funding startups. Twice a year, the company invests a small amount of money ($150k) in a large number of startups. The startup accelerator works intensively with the companies for three months, to get them into the best possible shape and refine their pitch to investors. Each cycle culminates in Demo Day when the startups present their companies to a carefully selected, invite-only audience.

Y Combinator

SP Investment Fund LLC and its affiliated funds have invested in scores of technology and real estate companies

SP Investment Fund

Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved. They know that real transformation takes time and that it is never a straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way. They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

Invus

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

StartX is a 501(c)(3) Stanford-affiliated nonprofit in Silicon Valley that runs one of the world’s top startup accelerator programs. Its mission is to advance the development of the best entrepreneurs through experiential education and peer learning. Since launching in 2010, it has supported more than 450 companies and 1000 entrepreneurs, from early to pre-IPO stage, working across a wide spectrum of industries.    StartX and StartX Med, dedicated to medical and biotechnology innovation, provide founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. Based in Palo Alto, the accelerator also operates StartX-QB3 Labs and the Stanford-StartX Fund. We are funded by Stanford University, Stanford Health Care, Microsoft, Steelcase, Hyundai, Oriza Ventures, Nissan, Panasonic, Lightspeed Venture Partners, Analog Devices, Silicon Valley Bank, Greylock Partners, Sequoia Capital, and many others. For more information, visit startx.com The company is associated investment vehicle, the Stanford-StartX Fund is a partnership between StartX, Stanford University and Stanford Health Care.  It can invest only in StartX companies who raise qualified rounds of venture capital using objective criteria; it is founder opt-in.

StartX (Stanford-StartX Fund)

SV Tech Ventures focuses its investments primarily on companies that have successfully demonstrated their capabilities to develop advanced technologies.

SV Tech Ventures

UpHonest Capital is an early-stage, industry-agnostic venture capital firm that partners with companies from pre-seed stage to Series A. The firm invests in entrepreneurs and early-stage startups and then uses its resources to boost value creation through disruptive means.

UpHonest Capital

Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta

Shangbay Capital

Propel(x) is an angel investing platform focused on funding early-stage companies that are built around scientific discovery.  The company is driven by a mission to help propel mankind by enabling investments in technologies that matter.  Propel(x) was founded in 2014 and is headquartered in San Francisco, California.

Propel(X)

MedTech Venture Partners fund and support medical technology entrepreneurs.

MedTech Venture Partners

Newton Fund

Golden Seeds is a seed-stage investment firm with a focus on women leaders. Their investment thesis rests on the extensive research that concludes that gender-diverse teams produce a better return on equity. By seeking companies where women hold leadership positions and own substantial equity, they are funding companies that are likely to have diverse perspectives that will contribute to success.

Golden Seeds

Astia Angels is a global network of both female and male angel investors that invest in high-growth companies. The angel investor network is actively engaged in the Astia community and screening process (Astia Expert Sift TM) and founded by experienced angel investors. All members are highly involved throughout the investment process and make independent investment decisions.

Astia Angels

Invus Opportunities is a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Invus Opportunities is focused on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunities brings a complementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities both leads rounds of financing and co-invests in syndicated financings, and currently manages over $1.5 billion.

Invus Opportunities

CloudStone Capital is an investment management company

CloudStone Capital

Zenflow

Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need.

Zenflow

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless